353 related articles for article (PubMed ID: 30446449)
1. The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer.
Jansen CS; Prokhnevska N; Kissick HT
Urol Oncol; 2019 Aug; 37(8):543-555. PubMed ID: 30446449
[TBL] [Abstract][Full Text] [Related]
2. Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer.
De Velasco MA; Kura Y; Fujita K; Uemura H
Int J Urol; 2024 Apr; 31(4):307-324. PubMed ID: 38167824
[TBL] [Abstract][Full Text] [Related]
3. Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy.
Peng S; Hu P; Xiao YT; Lu W; Guo D; Hu S; Xie J; Wang M; Yu W; Yang J; Chen H; Zhang X; Zhu Y; Wang Y; Yang Y; Zhu G; Chen S; Wang J; Zhang B; Chen W; Wu H; Sun Z; Ding T; Zhang H; Yi Z; Liu M; Ren S
Clin Cancer Res; 2022 Feb; 28(3):552-567. PubMed ID: 34740924
[TBL] [Abstract][Full Text] [Related]
4. Utilizing precision medicine to modulate the prostate tumor microenvironment and enhance immunotherapy.
Olson B; Patnaik A
Urol Oncol; 2019 Aug; 37(8):535-542. PubMed ID: 30503851
[TBL] [Abstract][Full Text] [Related]
5. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer.
Stultz J; Fong L
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):697-717. PubMed ID: 33820953
[TBL] [Abstract][Full Text] [Related]
6. Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy.
Prokhnevska N; Emerson DA; Kissick HT; Redmond WL
Adv Exp Med Biol; 2019; 1210():121-147. PubMed ID: 31900908
[TBL] [Abstract][Full Text] [Related]
7. The Tumor Immune Contexture of Prostate Cancer.
Vitkin N; Nersesian S; Siemens DR; Koti M
Front Immunol; 2019; 10():603. PubMed ID: 30984182
[TBL] [Abstract][Full Text] [Related]
8. Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden prostate cancer academy meeting.
Miyahira AK; Kissick HT; Bishop JL; Takeda DY; Barbieri CE; Simons JW; Pienta KJ; Soule HR
Prostate; 2015 Mar; 75(4):337-47. PubMed ID: 25358693
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
Ma Z; Zhang W; Dong B; Xin Z; Ji Y; Su R; Shen K; Pan J; Wang Q; Xue W
Theranostics; 2022; 12(11):4965-4979. PubMed ID: 35836810
[No Abstract] [Full Text] [Related]
10. The Role of Somatic Mutations on the Immune Response of the Tumor Microenvironment in Prostate Cancer.
Melo CM; Vidotto T; Chaves LP; Lautert-Dutra W; Reis RBD; Squire JA
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502458
[TBL] [Abstract][Full Text] [Related]
11. The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer.
Nair SS; Weil R; Dovey Z; Davis A; Tewari AK
Urol Clin North Am; 2020 Nov; 47(4S):e17-e54. PubMed ID: 33446323
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
Sun BL
Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
[TBL] [Abstract][Full Text] [Related]
13. Understanding the immune landscape and tumor microenvironment of pancreatic cancer to improve immunotherapy.
Torphy RJ; Schulick RD; Zhu Y
Mol Carcinog; 2020 Jul; 59(7):775-782. PubMed ID: 32166821
[TBL] [Abstract][Full Text] [Related]
14. Immune response drives outcomes in prostate cancer: implications for immunotherapy.
Meng J; Zhou Y; Lu X; Bian Z; Chen Y; Zhou J; Zhang L; Hao Z; Zhang M; Liang C
Mol Oncol; 2021 May; 15(5):1358-1375. PubMed ID: 33338321
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 1: Prostate Cancer Vaccines.
Patel A; Fong L
Oncology (Williston Park); 2018 Mar; 32(3):112-20. PubMed ID: 29548065
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for prostate cancer: False promises or true hope?
Rekoske BT; McNeel DG
Cancer; 2016 Dec; 122(23):3598-3607. PubMed ID: 27649312
[TBL] [Abstract][Full Text] [Related]
17. Clinical development of immunotherapy for prostate cancer.
Noguchi M; Koga N; Igawa T; Itoh K
Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
[TBL] [Abstract][Full Text] [Related]
18. Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory T cells and macrophages as adverse prognostic factors.
Andersen LB; Nørgaard M; Rasmussen M; Fredsøe J; Borre M; Ulhøi BP; Sørensen KD
J Pathol; 2021 Oct; 255(2):155-165. PubMed ID: 34255349
[TBL] [Abstract][Full Text] [Related]
19. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
Front Immunol; 2020; 11():784. PubMed ID: 32457745
[TBL] [Abstract][Full Text] [Related]
20. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]